Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.
Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.
The co-development project ends following a lack of clear and sufficient data to support efficacy in the results of a Phase III clinical trial in Japan.
Source: Seikagaku Corporation
Previous collaborations between the two companies include an agreement regarding exclusive marketing rights in Japan for SI-6603, a condoliase injection indicated for the treatment of lumbar disc herniation.
Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.
Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.
The co-development project ends...
Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.
Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.
The co-development project ends following a lack of clear and sufficient data to support efficacy in the results of a Phase III clinical trial in Japan.
Source: Seikagaku Corporation
Previous collaborations between the two companies include an agreement regarding exclusive marketing rights in Japan for SI-6603, a condoliase injection indicated for the treatment of lumbar disc herniation.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
